ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

AI Briefing

• – ImmunityBio secures $75M in non-dilutive financing to support global expansion and pipeline advancement.
• – Company's existing Royalty Interest Purchase Agreement with Oberland Capital increases total committed capital to $375M.
• – Amended agreement maintains existing terms, with a modest increase in royalty payback rate and royalty cap.